35.26

0.77% -0.275

After Hours: 35.26 0.005 +0.01%

Castle Biosciences Inc (CSTL)

Overview News Price History Option Chain Financials Why CSTL Down? Discussions Forecast

Castle Biosciences Inc stock is traded at $35.26, with a volume of 522.29K. It is down -0.77% in the last 24 hours and up +5.43% over the past month. Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

Previous Close:

$35.53

Open:

$36.1

24h Volume:

522.29K

Relative Volume:

1.35

Market Cap:

$1.08B

Revenue:

$339.92M

Net Income/Loss:

$-12.83M

P/E Ratio:

-82.08

EPS:

-0.4295

Net Cash Flow:

$4.52M

1W Performance:

+0.18%

1M Performance:

+5.43%

6M Performance:

+40.74%

1Y Performance:

+53.15%

1-Day Range:

$35.17

$36.99

1-Week Range:

$34.14

$36.99

52-Week Range:

$17.72

$44.28

Castle Biosciences Inc Stock (CSTL) Company Profile

Name

Castle Biosciences Inc

Sector

Healthcare (1068)

Industry

Diagnostics & Research (50)

Phone

866-788-9007

Address

1500 W. PARKWOOD AVE., FRIENDSWOOD, TX

Employee

942

Twitter

@castlebio

Next Earnings Date

2026-11-02

Latest SEC Filings

CSTL's Discussions on Twitter

Compare CSTL vs TMO, DHR, NTRA, A, IQV

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CSTL Castle Biosciences Inc	35.26	1.09B	339.92M	-12.83M	4.52M	-0.4295
TMO Thermo Fisher Scientific Inc	652.51	249.58B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	211.76	157.81B	24.78B	3.68B	5.29B	5.1743
NTRA Natera Inc	408.47	59.47B	2.50B	-226.32M	71.51M	-1.6412
A Agilent Technologies Inc	166.68	48.71B	7.23B	1.41B	1.09B	4.979
IQV Iqvia Holdings Inc	260.72	44.50B	16.63B	1.39B	2.12B	8.0674

Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-14-23	Initiated	Guggenheim	Buy
Jan-05-23	Initiated	Scotiabank	Sector Outperform
Jan-07-22	Initiated	Stephens	Overweight
Apr-30-21	Initiated	Lake Street	Buy
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight
Dec-27-19	Reiterated	Canaccord Genuity	Buy
Aug-19-19	Initiated	BTIG Research	Buy
Aug-19-19	Initiated	Canaccord Genuity	Buy
Aug-19-19	Initiated	Robert W. Baird	Outperform
Aug-19-19	Initiated	SVB Leerink	Outperform

View All

Castle Biosciences Inc Stock (CSTL) Latest News

03:56 AM

Bank of America Corp DE Makes New $2.35 Million Investment in Castle Biosciences, Inc. $CSTL - MarketBeat

03:56 AM

Sep 30, 2026

Precision Trading with Castle Biosciences Inc. (CSTL) Risk Zones - Stock Traders Daily

Sep 30, 2026

Low-risk melanoma patients who skipped lymph node biopsy had 99.6% recurrence-free survival at five years. - Stock Titan

Sep 30, 2026

Sep 28, 2026

Castle Biosciences (CSTL) Study Validates TissueCypher Test's Im - GuruFocus

Sep 28, 2026

A test changed doctors’ plans for 90% of patients with the same precancerous esophagus condition. Their risks differed. - Stock Titan

Sep 28, 2026

Sep 27, 2026

Castle Biosciences CEO sells $512k in stock - Investing.com

Sep 27, 2026

Sep 26, 2026

Form 4 Castle Biosciences Inc For: 26 September By Investing.com - Investing.com Nigeria

Sep 26, 2026

Castle Biosciences (NASDAQ:CSTL) Upgraded to "Buy" at Wall Street Zen - MarketBeat

Sep 26, 2026

Sep 25, 2026

Texas bioscience firm expands in Scottsdale as AZ headcount tops 200 - The Business Journals

Sep 25, 2026

Sep 24, 2026

New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx™ - PR Newswire

Sep 24, 2026

Sep 23, 2026

Castle Biosciences (NASDAQ:CSTL) Insider Derek Maetzold Sells 8,580 Shares - MarketBeat

Sep 23, 2026

Sep 22, 2026

CSTL Looks 17.2% Overvalued on GF Value™ as Market Prices in Str - GuruFocus

Sep 22, 2026

Castle Biosciences opens 55,000 sq ft Arizona lab facility By Investing.com - Investing.com Canada

Sep 22, 2026

Castle Biosciences to Open New Lab in Arizona - marketscreener.com

Sep 22, 2026

Castle Biosciences opens 55,000 sq ft Arizona lab facility - Investing.com

Sep 22, 2026

Castle Biosciences,Opens New Laboratory And Office Facility In Scottsdale, Arizona - TradingView

Sep 22, 2026

Castle Biosciences to Open New Laboratory Facility in Scottsdale - PR Newswire

Sep 22, 2026

Sep 21, 2026

Castle Biosciences (CSTL) Insider Trading Activity 2026 $CSTL - MarketBeat

Sep 21, 2026

Sep 18, 2026